Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease

Claudia R. Morris, Gregory J. Kato, Mirjana Poljakovic, Xunde Wang, William C. Blackwelder, Vandana Sachdev, Stanley L. Hazen, Elliott P. Vichinsky, Sidney M. Morris, Mark T. Gladwin

Research output: Contribution to journalArticle

Abstract

Context. Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of L-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes. Objective. To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality. Design Plasma amino acid levels, plasma and erythrocyte arginase activities, and pulmonary hypertension status as measured by Doppler echocardiogram were prospectively obtained in outpatients with sickle cell disease. Patients were followed up for survival up to 49 months. Setting. Urban tertiary care center and community clinics in the United States between February 2001 and March 2005. Participants. Two hundred twenty-eight patients with sickle cell disease, aged 18 to 74 years, and 36 control participants. Main Outcome Measures. Plasma amino acid levels, plasma and erythrocyte arginase activities, diagnosis of pulmonary hypertension, and mortality. Results. Plasma arginase activity was significantly elevated in patients with sickle cell disease, with highest activity found in patients with secondary pulmonary hypertension. Arginase activity correlated with the arginine-ornithine ratio, and lower ratios were associated with greater severity of pulmonary hypertension and with mortality in this population (risk ratio, 2.5; 95% confidence interval [CI], 1.2-5.2; P=.006). Global arginine bioavailability, characterized by the ratio of arginine to ornithine plus citrulline, was also strongly associated with mortality (risk ratio, 3.6; 95% CI, 1.5-8.3; P<.001). Increased plasma arginase activity was correlated with increased intravascular hemolytic rate and, to a lesser extent, with markers of inflammation and soluble adhesion molecule levels. Conclusions. These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide. The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease.

Original languageEnglish (US)
Pages (from-to)81-90
Number of pages10
JournalJournal of the American Medical Association
Volume294
Issue number1
DOIs
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease'. Together they form a unique fingerprint.

  • Cite this

    Morris, C. R., Kato, G. J., Poljakovic, M., Wang, X., Blackwelder, W. C., Sachdev, V., Hazen, S. L., Vichinsky, E. P., Morris, S. M., & Gladwin, M. T. (2005). Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Journal of the American Medical Association, 294(1), 81-90. https://doi.org/10.1001/jama.294.1.81